ECOG Performance Status is a simple 0-to-5 scale doctors use to rate how well a patient can carry out everyday activities despite their illness. A score of 0 means fully active, 1 means restricted from strenuous activity but able to do light work, 2 means up and about more than half the day but unable to work, 3 means confined to bed or chair more than half the day, 4 means completely disabled and bedbound, and 5 means deceased. It is one of the most important factors oncologists use to decide whether a patient is strong enough for surgery, chemotherapy, immunotherapy, or clinical trial enrollment.
Origin
Developed by the Eastern Cooperative Oncology Group, a U.S. cancer research consortium, and published by Dr. Martin Oken and colleagues in 1982 in the American Journal of Clinical Oncology. It is sometimes called the Zubrod score, after Dr. C. Gordon Zubrod, who proposed an earlier version in the 1960s.
Significance in Asbestos Context
For patients with mesothelioma or asbestos-related lung cancer, the ECOG score often determines which treatments are even offered. Aggressive options such as extrapleural pneumonectomy, pleurectomy/decortication, or platinum-based chemotherapy combined with immunotherapy are usually reserved for patients with ECOG 0 or 1; many clinical trials exclude patients with ECOG 2 or worse. The score also appears repeatedly in oncology notes and becomes important evidence in a legal claim, because it documents how the disease has progressively limited the patient's ability to work, care for themselves, and enjoy life, directly supporting damages for pain, suffering, lost earnings, and loss of household services.
Example Sentence
The oncologist noted that his ECOG performance status had declined from 1 to 3 over four months, which both ruled out second-line chemotherapy and supported the family's claim for diminished quality of life.
Related Terms
Karnofsky Performance Status, Mesothelioma, Prognosis, Quality of Life Damages, Palliative Care, Clinical Trial Eligibility
Notes
- Ask your oncologist to record your ECOG score at every visit and request copies of those notes; a documented trajectory (for example, 1 → 2 → 3) is powerful evidence of disease progression for both treatment planning and legal damages.
- If you are told you do not qualify for a treatment or trial because of your ECOG score, ask whether physical therapy, nutritional support, or treatment of a specific symptom (pain, effusion, anemia) could improve your score enough to become eligible.
- Keep a personal daily log of what you can and cannot do (walking distance, stairs, dressing, meal preparation) because your own description can correct an ECOG score that was assigned during a brief clinic visit.
- Share ECOG documentation with your legal team early; it supports non-economic damages and, in wrongful death cases, helps establish the pace of decline before death.
In the research library
20 studies in our medical research library mention ECOG Performance Status in the title or abstract. Among the most cited:
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trialG.V. Scagliotti, R. Gaafar, A.K. Nowak, et al, 2019 · The Lancet. Respiratory Medicine · cited 122 times
- Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trialC. Pinto, P.A. Zucali, M. Pagano, et al, 2021 · The Lancet. Oncology · cited 86 times
- A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesotheliomaA.K. Nowak, A.M. Cook, A.M. McDonnell, et al, 2015 · Annals of Oncology · cited 85 times
- Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trialsG.L. Ceresoli, B. Castagneto, P.A. Zucali, et al, 2008 · British Journal of Cancer · cited 76 times
- The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapyM. Deraco, D. Baratti, I. Hutanu, et al, 2013 · Annals of Surgical Oncology · cited 67 times
The journals that publish most on it: Annals of Surgical Oncology (3), Lung Cancer (2), Annals of Oncology (2).
Category: Diagnostic Tools & Biomarkers · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.